Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Status:
Completed
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
The objective of this phase III trial is to establish statistical equivalence in terms of
efficacy (best overall response rate [ORR], proportion of patients with complete response
[CR] plus partial response [PR]) until 18 weeks of first-line treatment with BI 695502 plus
chemotherapy versus Avastin® plus chemotherapy followed by maintenance monotherapy with
either BI 695502 or Avastin®.